Health / Medical Topics

    NF-kB

    Definition 1

    NF-kB is a heterodimer complex of two DNA-binding subunits from two families of ubiquitous, inducible, nuclear transcription activators involved in cytokine-induced activation of gene expression. NFKB1 or NFKB2 is bound to REL, RELA, or RELB to form the NF-kB complex. NF-kB is inhibited by IkB proteins (NFKBIA or NFKBIB), which inactivate NF-kB by trapping it in the cytoplasm. Phosphorylation of IkB by kinases (IKBKA or IKBKB) marks them for ubiquitination, allowing NF-kB translocation to the nucleus and DNA binding at kappa-B transcription enhancer motifs. In B-lymphocytes, NF-kB binds to the immunoglobulin kappa light chain enhancer and in T-lymphocytes it binds to enhancers in virally infected cells, including HIV. (from OMIM 164011, 164012, 164910, 164014, 604758, and NCI) (NCI Thesaurus)

    Definition 2

    Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. (NLM, Medical Subject Headings)

    Definition 3

    family of transcription factors involved in cytokine-induced activation of gene expression by binding to the enhancer; essential for HIV expression. (NIH CRISP Thesaurus)




    YOU MAY ALSO LIKE

    NF-kappa-B essential modulator (419 aa, ~48 kDa) is encoded by the human IKBKG gene. This protein plays a role in the mediation…
    A group of proteins that help control many functions in a cell, including cell growth and survival. These proteins also control the…
    NFAT is a multi-subunit transcription complex that includes homo- or hetero-dimers of FOS and JUN proteins. NFATC, the Dorsal/Rel family cytosolic…
    Any of the electronic health record systems and solutions developed by the NextGen corporation.
    The next improvement of a device, procedure, technique, or service that provides a significant improvement in the state of the art. …
    The identifier of the subsequent trial that the patient is entering.

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact